SCHEMBL3007239

SCHEMBL3007239

O=S(=O)(c1ccc(F)cc1)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.40
HTR2C P28335 7/20 0.40
KCNH2 Q12809 7/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 1/20 0.40
DRD2 P14416 3/20 0.40
EPHX2 P34913 1/20 0.39
MAPT P10636 2/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GPR6 P46095 1/20 0.35
CCR5 P51681 1/20 0.35
MAPK1 P28482 1/20 0.35
CTSS P25774 1/20 0.35
ALOX5 P09917 1/20 0.35
FPR2 P25090 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011420 0.94 HTR2A (0.42) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3014815 0.94 L3MBTL1 (0.41) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3017935 0.93 HTR2A (0.35) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3010530 0.93 HTR2A (0.35) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3016901 0.93 GBA1 (0.39) HTR2AHTR2CKCNH2SMN1; SMN2ALDH1A1
SCHEMBL3014833 0.93 L3MBTL1 (0.35) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3021363 0.93 HTR2A (0.42) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3004485 0.92 HTR2A (0.36) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3015894 0.92 MAPT (0.35) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1
SCHEMBL3014406 0.92 HTR2A (0.42) HTR2AHTR2CKCNH2SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR2A 752/4885HTR2C 1153/4885KCNH2 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.